Secukinumab gets FDA nod for nr-axSpA
05 Aug 2020
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
DGAT2 a potential therapeutic target for fatty liver?
05 Aug 2020
Antisense inhibition of DGAT2* – one of two vital enzymes in triglyceride synthesis – may be a favourable strategy for reversing nonalcoholic fatty liver disease (NAFLD), suggesting that targeting this pathway may mitigate NAFLD progression to its more severe form, nonalcoholic steatohepatitis (NASH), a phase II study has shown.
Contents : Co-amoxiclav (amoxicillin & clavulanic acid). Per Zisuva 625 FC tab Amoxicillin 500 mg, clavulanic acid 125 mg. Per Zisuva 1G FC tab Amoxicillin 875 mg, clavulanic acid 125 mg
Indications/Uses : Otitis media, sinusitis, & infections caused by susceptible organisms involving the lower resp tract, skin & skin structure, & urinary tract w/ additional coverage of β-lactamase producing B. catarrhalis, H. influenzae, N. gonorrhoeae, & S. aureus (not MRSA) in patients w/ amoxicillin resistance & those who cannot tolerate alternative treatments.
Sign Out
